
GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics. The deal sees GSK pay $50 million …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

